<DOC>
	<DOC>NCT00398151</DOC>
	<brief_summary>To evaluate the changes in proinflammatory markers (ltd4 in urine) and eosinophil from peripheral blood after newly initiated montelukast therapy.</brief_summary>
	<brief_title>To Evaluate the Inflammatory Markers in Adult Patients With Asthma Associated With Allergic Rhinitis Receiving Montelukast Therapy (0476-366)</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Rhinitis, Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>Allergic rhinitis symptoms: sneezing, rhinorrhea, obstruction of the nasal passages, itchy nose and throat, and conjunctival Male or female outpatient 20 years of age and older Patients with the following signs and symptoms of asthma and allergic rhinitis: history of cough, wheezing, shortness of breath, positive methacholine bronchoprovocation test Active, acute or chronic, pulmonary disorder (besides asthma) documented by history, physical examination, or chest xray. history of anaphylactic or hypersensitive to study drug Requires oral, intravenous, or intramuscular corticosteroids on daily routine basis Started on immunotherapy within six months before the prestudy visit and/or the dose of immunotherapy is expected to change over the course of the study Treated with montelukast within 3 months before enrollment Unable to perform acceptable, reproducible spirometry and peak flow measurement Unresolved symptoms and signs of an upper respiratory tract infection (uri) within 2 weeks prior to visit 1</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>